Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
Published inAnnals of the rheumatic diseases, vol. 71, no. 3, p. 374-377
Publication date2012
Abstract
Keywords
- Adult
- Aged
- Antibodies, Monoclonal, Murine-Derived/adverse effects/therapeutic use
- Antirheumatic Agents/adverse effects/therapeutic use
- Arthritis, Rheumatoid/drug therapy
- Drug Therapy, Combination
- Epidemiologic Methods
- Female
- Humans
- Immunosuppressive Agents/adverse effects/therapeutic use
- Isoxazoles/administration & dosage/adverse effects
- Male
- Methotrexate/administration & dosage/adverse effects
- Middle Aged
- Product Surveillance, Postmarketing/methods
- Treatment Outcome
Affiliation
Research group
Citation (ISO format)
CHATZIDIONYSIOU, Katerina et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. In: Annals of the rheumatic diseases, 2012, vol. 71, n° 3, p. 374–377. doi: 10.1136/annrheumdis-2011-200003
Main files (1)
Article (Published version)
Identifiers
- PID : unige:32495
- DOI : 10.1136/annrheumdis-2011-200003
- PMID : 21972242
ISSN of the journal0003-4967
